Mutual Fund Details
NAV
₹611.4619
as on 15 May 2026, 11:22 PM
₹2.5785(0.42%)
Last Change
Scheme Ratings
3
rated byValue Research
Pharma
Rankings based on | as on Invalid date
×
Download the Paytm Money app now!
Invest in Stocks, F&O, Mutual Funds, IPOs, NFOS and Bonds.
Zero brokerage for 30 days- Zero account opening fees
- Zero AMC for life
Scan QR code to download the app
Investment Performance
would have given a return of
₹1,10,871
₹1,21,647
₹1,90,817
₹1,96,033
Bank Account
Fixed Deposit
Regular Mutual Fund
This Fund on Paytm Money
This Mutual Fund
₹96,033
Profit (absolute return)
96.03%
in the last
1m
3m
1y
3y
5y
max
+1% Higher Returns
With Direct Plans on Paytm MoneyInvestment Returns
In the last 1 month
9.31%
In the last 3 months
8.22%
In the last 6 months
4.98%
In the last 1 year
10.90%
In the last 3 years
96.03%
In the last 5 years
98.33%
In the last 10 years
345.01%
Absolute Returns
CAGR
Scheme Riskometer
low
low to moderate
moderate
moderately high
high
very high
Investors understand that their principal will be at very high risk
Scheme Information
Nippon India Pharma Fund Direct-Growth
as of 30 Apr 2026, 05:30 AM
₹8,365.40 Cr
Scheme Asset Size
Fund Type
Open-End
Exit Load
Exit load of 1% if redeemed within 1 month.
1.48%
Expense Ratio
Plan
Growth
Benchmark
BSE Healthcare Total Return Index
Exit Load
Exit load of 1% if redeemed within 1 month.
Scheme Document
Sectors Holding in this Mutual Fund
as on30 Apr 2026
Healthcare
99.45%
₹8,319.39 Cr
Cash Holding
0.54%
₹45.17 Cr
Others
0.01%
₹83.65 Lakh
Companies Holding in this Mutual Fund
as on30 Apr 2026
Sun Pharmaceutical Industries Ltd.
13.92%
₹1,164.46 Cr
Lupin Ltd.
8.45%
₹706.88 Cr
Divi's Laboratories Ltd.
6.41%
₹536.22 Cr
Dr. Reddy's Laboratories Ltd.
5.96%
₹498.58 Cr
Cipla Ltd.
5.42%
₹453.40 Cr
Others
59.84%
₹5,005.86 Cr
View All
View All
This fund's returns:
25.08%Return Duration
3 Years
ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund Direct - Growth
EquityPharma
Min. Investment
₹100
Category Returns
21.86%
29.48%
3Y Returns
29.48
UTI Healthcare Fund Direct-Growth
EquityPharma
Min. Investment
₹500
Category Returns
21.86%
29.48%
3Y Returns
28.28
Mirae Asset Healthcare Fund Direct - Growth
EquityPharma
Min. Investment
₹100
Category Returns
21.86%
29.48%
3Y Returns
28.15
AboutNippon India Pharma Fund Direct-Growth
Nippon India Pharma Fund Direct-Growth is aEquity mutual fund scheme fromNippon India Mutual Fund. This scheme was launched onInvalid date. It has an AUM of ₹8,365.40 Crores and the latest NAV decalared is ₹611.462 as on16 May 2026 at12:09 am.
Nippon India Pharma Fund Direct-Growth scheme return performance in last 1 year is 10.90%, in last 3 years is 96.03% and 771.52% since scheme launch. The min. SIP amount to invest in this scheme is ₹100.
Scheme Details
| AUM: | ₹8,365.40 Cr |
| Category: | Equity: Sectoral-Pharma |
| Launch Date: | Invalid date |
| Fund Type: | Open-End |
AMC Information
Nippon India Mutual Fund
View AMC Details
₹7,49,710.38 Cr
AUM
298
Schemes
Address
30th Floor, One Lodha PlaceSenapati Bapat Marg, Lower ParelMumbai400013
Phone Number
Phone :+91 022 6808 7000
Fax :+91 022 6808 7097
Email / Website
Start investing in minutes
Download app to Explore
Scan this QR code to download the app now!
Or download from
